Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Montelukast as Adjuvant Therapy in Obese Patients With Type 2 Diabetes Mellitus
NCT04075110Phase 1Completed
- Sponsor
- Sadat City University
- Start
- Jul 2019
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of montelukast in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sadat City University. Primary endpoints: Change in Hemoglobin A1c at 12 weeks, Percent change in body weight at 12 weeks and 2 more. Started Jul 2019; status: completed.
02
Drugs
montelukast
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04075110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04075110.